Sanofi CEO Paul Hudson Outlines Bold M&A and R&D Strategy for a Transformative Year Ahead

At the JP Morgan Healthcare Conference, Sanofi CEO Paul Hudson outlined the company’s forward-looking strategy, emphasizing a keen interest in mergers and acquisitions (M&A), focusing on “game-changing science.” Hudson highlighted Sanofi’s strength in immunology and the intention to target specific patient populations. He underscored the company’s increased R&D investment and plans to advance 12 potential blockbusters, primarily in immunology and inflammation, each with a projected peak sales potential of over €2 billion. Hudson also expressed confidence in Sanofi’s commercial capabilities, referencing the successful launch of Beyfortus, a respiratory syncytial virus (RSV) preventive therapy developed with AstraZeneca. This launch exceeded expectations, leading to a significant increase in production to meet high demand. Hudson concluded by expressing pride in Sanofi’s progress and transformation under his leadership, signaling a promising future for the company.

To read more, click here.

[Source: Endpoints, January 9th, 2023]